Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma.
Humans
Neurilemmoma
/ metabolism
p21-Activated Kinases
/ metabolism
Cell Proliferation
/ drug effects
Hippo Signaling Pathway
Neurofibromin 2
/ genetics
Signal Transduction
/ drug effects
Protein Serine-Threonine Kinases
/ metabolism
Cell Line, Tumor
Transcription Factors
/ metabolism
Apoptosis
/ drug effects
Drug Synergism
Neurofibromatosis 2
/ metabolism
YAP-Signaling Proteins
/ metabolism
Protein Kinase Inhibitors
/ pharmacology
Adaptor Proteins, Signal Transducing
/ metabolism
DNA-Binding Proteins
/ metabolism
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
22
01
2024
accepted:
23
05
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Neurofibromatosis type 2 is a genetic disorder that results in the formation and progressive growth of schwannomas, ependymomas, and/or meningiomas. The NF2 gene encodes the Merlin protein, which links cell cortical elements to the actin cytoskeleton and regulates a number of key enzymes including Group I p21-activated kinases (PAKs), the Hippo-pathway kinase LATS, and mTORC. While PAK1 and PAK2 directly bind Merlin and transmit proliferation and survival signals when Merlin is mutated or absent, inhibition of Group 1 PAKs alone has not proven sufficient to completely stop the growth of NF2-deficient meningiomas or schwannomas in vivo, suggesting the need for a second pathway inhibitor. As the Hippo pathway is also activated in NF2-deficient cells, several inhibitors of the Hippo pathway have recently been developed in the form of YAP-TEAD binding inhibitors. These inhibitors prevent activation of pro-proliferation and anti-apoptotic Hippo pathway effectors. In this study, we show that PAK inhibition slows cell proliferation while TEAD inhibition promotes apoptotic cell death. Finally, we demonstrate the efficacy of PAK and TEAD inhibitor combinations in several NF2-deficient Schwannoma cell lines.
Identifiants
pubmed: 39083549
doi: 10.1371/journal.pone.0305121
pii: PONE-D-24-02417
doi:
Substances chimiques
p21-Activated Kinases
EC 2.7.11.1
Neurofibromin 2
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
Transcription Factors
0
NF2 protein, human
0
YAP-Signaling Proteins
0
Protein Kinase Inhibitors
0
Adaptor Proteins, Signal Transducing
0
DNA-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0305121Informations de copyright
Copyright: © 2024 Benton et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.